Loading...
•
Jun 30
Corcept Therapeutics Q2 2025 Earnings Report
Corcept Therapeutics reported its second quarter 2025 financial results, showing increased revenue but a slight decrease in net income and EPS compared to the previous year.
Key Takeaways
Corcept Therapeutics experienced robust growth in its hypercortisolism business, achieving record numbers of new prescribers and patients. Despite this, financial results were impacted by a specialty pharmacy vendor's capacity issues. The company reported increased revenue year-over-year but a slight decline in net income and diluted EPS. Corcept also provided an updated revenue guidance for 2025.
Second quarter 2025 revenue increased to $194.4 million, up from $163.8 million in Q2 2024.
Net income for Q2 2025 was $35.1 million, a slight decrease from $35.5 million in Q2 2024.
Diluted EPS for Q2 2025 was $0.29, down from $0.32 in Q2 2024.
Cash and investments stood at $515.0 million as of June 30, 2025, reflecting significant stock repurchases.
Corcept Therapeutics
Corcept Therapeutics
Corcept Therapeutics Revenue by Segment
Revenue by Segment
Product Revenue, Net Revenue
CapyFin.com Forward Guidance
Corcept Therapeutics modified its 2025 revenue guidance to $850 – $900 million, expecting improved performance from its current specialty pharmacy vendor and the addition of a second pharmacy. The company is also advancing multiple clinical programs with key regulatory milestones and study results anticipated.
Positive Outlook
- Modified 2025 revenue guidance of $850 – $900 million, indicating expected growth.
- Anticipated improved performance from the current specialty pharmacy vendor and contribution from a second pharmacy.
- FDA review of Relacorilant NDA for hypercortisolism continues with a PDUFA date of December 30, 2025.
- NDA submitted for Relacorilant to treat platinum-resistant ovarian cancer, with European MAA submission expected soon.
- Exploratory analysis of DAZALS trial showed dazucorilant significantly reduced the risk of death in ALS patients.
Challenges Ahead
- Financial results in Q2 2025 did not fully reflect the surge in demand due to specialty pharmacy vendor's capacity issues.
- DAZALS trial for ALS did not meet its primary endpoint of improvement in the ALS Functional Rating Scale-Revised (ALSFRS-R).
- Potential for increased uptake or price reductions in competing medications, including generic versions of Korlym, could affect revenue.
- The timing and outcome of clinical trials and regulatory approvals are subject to inherent uncertainties.
- No specific negative financial guidance was provided beyond the general risks associated with forward-looking statements.